Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. - Wikidata - awgldk - TriplyDB

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

http://www.wikidata.org/entity/Q33343227

about

Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target Pure small cell carcinoma of the prostate: a case report and literature review Neuroendocrine differentiation in prostate cancer The many faces of neuroendocrine differentiation in prostate cancer progression Etoposide, vincristine, doxorubicin and dexamethasone (EVAD) combination chemotherapy as second-line treatment for advanced AIDS-related Kaposi's sarcoma.The molecular basis for ethnic variation and histological subtype differences in prostate cancer.Utility of FDG-PET in clinical neuroendocrine prostate cancer.Establishing prostate cancer patient derived xenografts: lessons learned from older studies Unusual subtypes of prostate cancer.PC3 is a cell line characteristic of prostatic small cell carcinoma.Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens.Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center.A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.Platinum-based chemotherapy for variant castrate-resistant prostate cancer.Evolving perspectives of the role of novel agents in androgen-independent prostate cancer.TRIIODOTHYRONINE ATTENUATES PROSTATE CANCER PROGRESSION MEDIATED BY β-ADRENERGIC STIMULATION Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.Modeling a lethal prostate cancer variant with small-cell carcinoma features.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Review of small cell carcinomas of the prostate.Histological variants of prostatic carcinoma and their significance.Small cell carcinoma of the prostate.Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Genitourinary small cell malignancies: prostate and bladder.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Chemotherapy in Prostate Cancer.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.Small Cell Carcinoma of the Prostate in an Elderly Patient: A Case Report and Review of the Literature Emerging Variants of Castration-Resistant Prostate Cancer.

P2860

Q24608574-D312D825-E0F4-4C00-9AAE-CA4C602C4B61 Q24623117-18D89B01-FD12-4A5F-89FC-CF10498A7BDB Q24657547-477A3509-0240-485A-9080-C0F364746999 Q26992049-4E1782C5-1B5A-4E09-AB6D-09066FA435B7 Q33398711-C72668E1-5ABE-405F-BEB1-4E0022242085 Q33835864-2EA79C88-0ADA-49A8-AC9A-F425FC7A9BC0 Q35166475-31C06258-2CB4-47D0-9656-94A3B50B8C55 Q35556598-81C784B2-79E0-4DD2-B066-6BCEAEDEAC87 Q35672159-89A00088-6322-4CD4-A377-01EA5953C7B3 Q36185201-D5D09A9D-8D50-4274-91ED-EEDDE75EB438 Q36194953-6425F3A7-0490-4AAD-BEDE-EDD99D3A4CF8 Q36241242-AC5C4793-0425-4628-B79E-F1BCD26D18DB Q36272854-B7EDEC7F-1812-4238-8A80-E15F35A619CE Q36421105-F50B18B3-A616-47F2-941F-4498C54C3DE4 Q36621110-4CCFB605-DA03-49CB-B944-627680DCF972 Q36688923-B27B0321-BE1D-47D5-BF63-84C6C84E636F Q36862668-A30BAEC8-6069-4CA9-B0B6-C17EF1B1B3A0 Q36977870-917F68A1-58E3-4980-8C20-4FB839E4C7F8 Q37197722-29BEF8E7-8C01-4682-8622-BE7C412FDD47 Q37216993-F02A91A8-2B6C-4A86-8786-6D68A9968E26 Q37417870-943F9371-F403-4F1F-9091-7139A3621DAF Q37444366-B90B0CAC-2038-4C41-911D-63A03A0993DA Q37564369-CD606380-D46A-4241-A8C8-63ACA4D1B467 Q37582049-3DFAE9AF-AB0C-47EC-840A-D66DFCF5450B Q37677557-8E95C7C1-50F2-4AD1-81E3-6B24D7CF0812 Q37910715-D89D5907-EEE6-4AD2-91D5-6CD2D026B1E1 Q37950459-839A07D0-6FA7-47F6-B270-CD0EEDD4042A Q37960020-AD1CFB10-B64F-43C2-B42B-843B7803D9CD Q37972700-6E920FC8-0626-43ED-A43B-5327556604A2 Q38188869-3733FD10-76E9-4C48-975E-5A0BF1F51EAF Q38209356-AEF17A35-3B89-4E0F-A91D-476BD4A56C08 Q38352874-E655821D-DBE1-4D97-BDED-1495C016117B Q38362686-F2753214-2B09-4D0C-8486-CA708A33FDEB Q38374417-E05A0B25-1351-4D56-B415-7A97E11DAA57 Q38555599-B31A0A8D-C8D7-4275-9587-418E30968745 Q38930155-DCA57898-B970-4811-9A5D-C15A8EB760C0 Q39044979-F978C33C-BDF3-4134-9A86-D48F5DEBE7EC Q39051290-7235FF61-3BD0-479C-95CC-FE6CE0DC726B Q39132763-97DB6767-A3C0-40D9-B1F1-ECBA89BA5ED8 Q39210257-0E0250E6-35FB-49A3-AEF8-4E97647DDC1E

P2860

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

http://www.wikidata.org/entity/Q33343227

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Results of a phase II study wi ...... ell carcinoma of the prostate.

@ast

Results of a phase II study wi ...... ell carcinoma of the prostate.

@en

type

label

Results of a phase II study wi ...... ell carcinoma of the prostate.

@ast

Results of a phase II study wi ...... ell carcinoma of the prostate.

@en

prefLabel

Results of a phase II study wi ...... ell carcinoma of the prostate.

@ast

Results of a phase II study wi ...... ell carcinoma of the prostate.

@en

P1433

Q33343227-7BC9AA12-FD57-47FF-83DE-C8093EBD9BB3

P1476

Q33343227-81978256-B13F-4A6E-8C84-240F8F496F0F

P2093

Q33343227-585BC5BF-224E-4033-AC1D-31E76136C2B0

Q33343227-5C640F99-CF28-4496-96D9-1776A244B001

Q33343227-604CB578-B6F6-409C-8BE1-626590D91858

Q33343227-94AF3581-906E-4992-BC18-431D50695B7E

Q33343227-9F0BE9DE-4068-4B0D-B73B-E2613A6693D5

Q33343227-B9517DBB-0023-4E0B-9555-96164C54AD6C

Q33343227-C412451B-3BF7-431C-9B71-70AACB556237

Q33343227-D27B7213-03A9-4D2B-A169-E266929F2ABC

P304

Q33343227-0FB8E389-6610-445B-B7EC-CE71FCD79966

P31

Q33343227-7190F696-8AB2-4313-A4AB-757067F50554

P356

Q33343227-155EEAE9-A488-41B2-8D04-B9D4463AE90E

P407

Q33343227-D32A0E17-D232-4330-9FAE-001A5305772F

P433

Q33343227-EFD80CC3-DDB8-42BC-964C-8520AD4D3209

P478

Q33343227-9AE2F67C-23D6-4E51-AB42-38B4B55E89B2

P577

Q33343227-4015C78F-55BD-435D-B803-1281AC4E998E

P698

Q33343227-04E82802-96BD-4E30-8F41-1C5D831BCD86

P356

JCO.2002.12.065

P1433

Journal of Clinical Oncology

P1476

Results of a phase II study wi ...... ell carcinoma of the prostate.

@en

P2093

Adriana Reyes

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Christos N Papandreou

http://www.w3.org/2001/XMLSchema#string

Danai D Daliani

http://www.w3.org/2001/XMLSchema#string

Patricia Troncoso

http://www.w3.org/2001/XMLSchema#string

Peter F Thall

http://www.w3.org/2001/XMLSchema#string

Shi-Ming Tu

http://www.w3.org/2001/XMLSchema#string

Xuemei Wang

http://www.w3.org/2001/XMLSchema#string

P304

3072-3080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.12.065

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12118020

http://www.w3.org/2001/XMLSchema#string